Mazdutide
[CAS# 2259884-03-0]

Identification

• Classification: API >> Inhibitor drug
• Name: Mazdutide
• Synonyms: 2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
• Molecular Formula: C₂₀₇H₃₁₇N₄₅O₆₅
• Molecular Weight: 4475.99
• CAS Registry Number: 2259884-03-0
• SMILES: C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N)O

Discovery and Applications

Madutectide is a novel synthetic peptide that is a breakthrough drug for the treatment of obesity and metabolic disorders. It was co-discovered by Chinese pharmaceutical researchers in the early 2020s. This multifunctional peptide targets multiple pathways involved in energy balance and appetite regulation.

Madutectide works by activating both the GLP-1 receptor and the glucagon receptor simultaneously. GLP-1 (glucagon-like peptide-1) enhances insulin secretion and reduces appetite, while glucagon promotes glucose production and energy expenditure. By combining these actions, madutectide helps regulate blood sugar levels and reduce weight, improving obesity and type 2 diabetes pathology.

Madutectide has shown great promise in weight loss clinical trials. It promotes weight loss by reducing appetite and increasing satiety, thereby reducing calorie intake. This dual action not only helps with weight loss, but also improves metabolic parameters such as blood sugar and lipid levels. Therefore, it provides a comprehensive approach to treating obesity-related diseases such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD).

In clinical trials, madutectide has been shown to significantly reduce weight compared to traditional weight loss drugs. Patients treated with madutide showed improvements in glycemic control and lipid profiles, suggesting its potential to be effective in managing weight and metabolic health.

In addition to its weight loss uses, madutide offers potential for treating chronic diseases associated with metabolic syndrome. Its ability to affect multiple pathways makes it a candidate for treating other metabolic diseases such as polycystic ovary syndrome (PCOS) and hypertension. In addition, current studies are exploring its effectiveness in enhancing cardiovascular health and improving liver function in patients with NAFLD.

References

2024. Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials. *American Journal of Therapeutics*, 31(5).
DOI: 10.1097/mjt.0000000000001756

2024. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. *Frontiers in Endocrinology*, 15.
DOI: 10.3389/fendo.2024.1309118

2023. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. *Nature Communications*, 14(1).
DOI: 10.1038/s41467-023-44067-4